Psoriasis is a long-term inflammatory skin disease that can affect overall health. People with psoriasis have a higher risk of developing insulin resistance, a condition in which the body does not respond properly to insulin. Insulin resistance can increase the risk of diabetes, heart disease, and other serious health problems. Because insulin resistance often develops without clear symptoms, many patients are not diagnosed early.
The purpose of this study is to identify which patients with psoriasis are more likely to develop insulin resistance and to create a tool that can help doctors estimate this risk for individual patients. The study will use existing medical records from two medical centers. Researchers will analyze information such as age, body weight, psoriasis severity, blood test results, other medical conditions, and medication history.
Machine learning methods will be used to analyze these data and build a prediction model. The model will be designed to be easy to understand, so doctors can see which factors contribute most to insulin resistance risk.
This study does not involve any new treatments or procedures. All patient information will be anonymized to protect privacy. The results may help doctors identify high-risk patients earlier and support timely monitoring and preventive care.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18 years or older
* Diagnosed with psoriasis (including plaque psoriasis, pustular psoriasis, erythrodermic psoriasis, or other clinically recognized subtypes), according to established clinical diagnostic guidelines
* Received medical care at Chinese PLA General Hospital (First Medical Center) or the collaborating center (Fourth Medical Center) during the study period
* Availability of complete medical records, including demographic information, relevant clinical characteristics, and laboratory data required to assess insulin resistance
Exclusion Criteria:
* Previous or current diagnosis of diabetes mellitus
* Presence of severe systemic diseases that may significantly affect glucose metabolism (such as malignant tumors, hyperthyroidism, or other serious endocrine disorders)
* Current or recent use of systemic medications known to affect insulin sensitivity, including:Systemic corticosteroids,Glucose-lowering medications, or Other medications with known significant effects on insulin resistance
* Pregnant or breastfeeding women
* Medical records with missing key variables required for the assessment of insulin resistance or model development
Primary outcome measure(s)
Insulin Resistance Status Assessed by the TyG Index — At baseline (using existing medical record data collected between January 2015 and June 2025) Insulin resistance will be evaluated using the triglyceride-glucose (TyG) index, calculated from fasting triglyceride and fasting plasma glucose levels obtained from medical records. Participants will be classified as having insulin resistance or not based on a predefined TyG index cutoff value (TyG ≥ 8.5)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.